Lundbeck: Important values are at stake
Danish drug group Lundbeck is far from pleased with last week’s verdict from an EU Court, which chose to uphold a massive fine handed to the company in 2013.
BY ELIZABETH MØNSTED JOHANSEN
Last week, The General Court under the EU Court of Justice in Luxembourg agreed with the EU Commission that Lundbeck had stifled competition in 2002 by striking pay-for-delay deals with a number of rivals and chose to uphold a historic fine of DKK 700 million – a decision that is hugely disappointing to the drug company.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
EU Court upholds Lundbeck fine
For abonnenter
Either Lundbeck or the EU Commission is lying
For abonnenter
This is what the appeal trials will cost for Lundbeck
For abonnenter
